Full spectrum flow cytometry and mass cytometry: A 32‐marker panel comparison. Issue 11 (20th May 2022)

• Record Type: Journal Article
• Authors: Jaimes, Maria C.; Leipold, Michael; Kraker, Geoffrey; Amir, El‐ad; Maecker, Holden; Lannigan, Joanne
• Other Names: Lannigan Joanne guestEditor.
• Is Part Of: Cytometry. Volume 101:Issue 11(2022)
• Page Start: 942
• Page End: 959
• Publication Date: 2022-05-20
• Subjects: Aurora -- CyTOF -- full spectrum flow cytometry -- high‐dimensional immunophenotyping -- mass cytometry; Flow cytometry -- Periodicals; Imaging systems in biology -- Periodicals; Imaging systems in medicine -- Periodicals; Diagnostic imaging -- Periodicals; 571.605
• DOI: 10.1002/cyto.a.24565
• Languages: English
• ISSNs: 1552-4922

Abstract

Abstract: High‐dimensional single‐cell data has become an important tool in unraveling the complexity of the immune system and its involvement in homeostasis and a large array of pathologies. As technological tools are developed, researchers are adopting them to answer increasingly complex biological questions. Up until recently, mass cytometry (MC) has been the main technology employed in cytometric assays requiring more than 29 markers. Recently, however, with the introduction of full spectrum flow cytometry (FSFC), it has become possible to break the fluorescence barrier and go beyond 29 fluorescent parameters. In this study, in collaboration with the Stanford Human Immune Monitoring Center (HIMC), we compared five patient samples using an established immune panel developed by the HIMC using their MC platform. Using split samples and the same antibody panel, we were able to demonstrate highly comparable results between the two technologies using multiple data analysis approaches. We report here a direct comparison of two technology platforms (MC and FSFC) using a 32‐marker flow cytometric immune monitoring panel that can identify all the previously described and anticipated immune subpopulations defined by this panel.